Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of [225Ac]-FPI-2059 in Adult Participants With NTSR1-Expressing Advanced, Metastatic and/or Recurrent Solid Tumours

Next Previous
Search
Trial Profile

A Phase 1 Study of [225Ac]-FPI-2059 in Adult Participants With NTSR1-Expressing Advanced, Metastatic and/or Recurrent Solid Tumours

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FPI 2059 (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Ewing's sarcoma; Gastric cancer; Head and neck cancer; Neuroendocrine tumours; Pancreatic cancer; Prostate cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Sponsors Fusion Pharmaceuticals

    • Most Recent Events

    • 28 Jan 2025 Status changed from recruiting to active, no longer recruiting.
    • 20 Mar 2023 According to a Fusion Pharmaceuticals media release, the company plans to provide guidance on timing for pharmacokinetic, imaging and safety data following early experience with FPI-2059 patient screening and enrollment.
    • 20 Mar 2023 According to a Fusion Pharmaceuticals media release, the first patient has been dosed in the study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top